Navigation Links
Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
Date:2/25/2008

hat NASH will become the leading cause of chronic liver disease in the next decade yielding 3-5 million patients in developed countries with fibrosis, cirrhosis and portal hypertension.

Currently, there are no approved pharmacological treatments available for portal hypertension, although off-label use of beta-blockers (i.e., propranolol, nadolol, timolol) has exhibited some reduction of bleeding. Beta-blocker therapy, however, is often contraindicated in portal hypertension patients (reported as high as 47% in one clinical trial) and is often not well tolerated leading to discontinuation of therapy (15%), and does not often meet treatment objectives of reducing portal vein pressure sufficiently in as many as 70% of patients treated. An effective long term treatment for life threatening variceal bleeding is thus needed.

Udenafil was approved for the treatment of erectile dysfunction in Korea under the brand name Zydena(R) in late December 2005 and has gained high patient acceptance among ED patients, garnering a market share of approximately 24% by volume during the third quarter of 2007. Udenafil is entering phase 3 clinical development in the USA for erectile dysfunction

Dong Hyun Park, President and CEO of Dong-A PharmTech, stated, "We are pleased to be working with Dr. Falk Pharma on evaluating the potential of our new long acting phosphodiesterase inhibitor, udenafil for treating portal hypertension. Dong-A PharmTech is continuing its development of udenafil for erectile dysfunction in the USA and will develop udenafil for other indications such as benign prostatic hyperplasia and pulmonary hypertension."

Ms. Ursula Falk, Managing Director of Dr. Falk Pharma commented, "Our partnership with Dong-A PharmTech for the development of udenafil for portal hypertension in Europe is extremely important for our company. Successful completion of this study will establish the effectiveness of udenafil as a potential new therapy for the greatly
'/>"/>

SOURCE Dong-A PharmTech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
4. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
5. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
6. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
7. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
8. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Markets and Technologies for Optical Coherence Tomography ...   STUDY OBJECTIVES ... this study is to offer synopsis of ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... MOUNTAIN VIEW, Calif. , May 21, 2013 /PRNewswire/ ... Brazil , Russia , ... (BRIC) are realizing there are no shortcuts.  This ... especially in the United States.  Companies must change the ... establishing value, customizing to local needs, and building regional ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4
... VIEW, Calif., Nov. 8, 2011 ChemoCentryx, Inc., today ... CCX354 at the Annual Meeting of the American College ... that specifically targets and inhibits the chemokine receptor known ... progression of rheumatoid arthritis (RA).  Results showed that CCX354 ...
... 8, 2011 Covance Inc. (NYSE: CVD ) ... Healthcare Conference on Thursday, November 10, 2011 at 3:00 p.m. ... at www.covance.com .  In order to register and download ... Covance, with headquarters in Princeton, New Jersey, is one ...
Cached Medicine Technology:ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 3ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 4Covance to Present at Credit Suisse 2011 Healthcare Conference 2
(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The federal ... hip replacement lawsuits in U.S. District Court, ... response to a request from Plaintiffs’ Counsel to conduct ... The May 17th Order grants that request, and ... conducted. (In re: Wright Medical Technology, Inc., Conserve Hip ...
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... May 21, 2013 Modern couples ... help of Texas Counseling’s Sexuality and Relationship Workshops, ... the development of healthier habits for their relationship. ... for both couples and individuals at Texas Counseling. ... relationships and learn skills to develop long term ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2
... ... Energy power system to supply all the loads in the new tower, including HVAC. ... as a practical matter, because east central Florida is hit frequently by hurricanes and thunderstorms ... ...
... , SAN PEDRO, Calif., Oct. 19 On ... the 11th annual surf cruise to Mexico will host their ... star line up of professional surfers, musicians, artists and movie ... The charity mission includes the W Hollywood Lions Club Global ...
... are already anticipating Halloween "trick or treating," some parents are ... to receive free candy. , Parents of children ... their child is the recipient of food outside the home. ... can stay safe without having to miss out on the ...
... (OTC Bulletin Board: OXBO) shareholders today voted to approve a ... general meeting in which shareholders also voted to approve all ... At the meeting, chairman and CEO Chris Stern also discussed ... Concentrate Gel for the skin care market and discussed an ...
... while blood flow is blocked protects tissue, animal study ... previous research, scientists have shown in animal studies that ... brain damage. , But it,s not a simple matter. ... depends on when 100 percent oxygen is given. ...
... no longer go after users or suppliers in states that ... News) -- The Obama administration has decided it will no ... the laws of states that allow use of the drug ... be sent in a Justice Department memo to federal prosecutors ...
Cached Medicine News:Health News:Florida's Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10-Story Emergency Facility 2Health News:Florida's Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10-Story Emergency Facility 3Health News:SURF CRUISE CUP 2009 2Health News:Halloween Doesn't Have to Be Scary for Kids With Food Allergies 2Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 2Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 3Health News:Timing of Oxygen After a Stroke May Matter 2Health News:U.S. Relaxes Opposition to Medical Marijuana 2Health News:U.S. Relaxes Opposition to Medical Marijuana 3
Inquire...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: